Stock Watch: Alnylam’s Date With The Competition
Meeting Endpoints With Less Competitive Data May Not Be A Win
Executive Summary
When a loss-making rare disease biotech company’s product takes on Pfizer in the same indication but without the benefit of superior data, pharmaceutical marketing lessons will be learnt.